Skip To Main Content
Rathi N Pillai on Muck Rack

Rathi N Pillai

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rathi N

Contact Rathi N, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic Non‒Small-Cell Lung Cancer: Brief Report on a Randomized, Open-label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

|
By Rathi N Pillai, Suresh S. Ramalingam, Janssen Research, Meena Thayu
| jtocrr.org
This paper is only available as a PDF. To read, Please Download here. ABSTRACT Introduction The programmed death-ligand 1 (PD-L1) inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced non‒small-cell lung cancer (NSCLC). Preclinical studies indicate that targeting CD38+ cells with daratumumab may synergistically enhance atezolizumab’s antitumor activity by increasing effector T-cell activity.
Open in Who Shared Issue with article?
|
By Padmanee Sharma, Margaret K. Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Patrick A. Ott, Michael Morse, Dirk Jaeger, Emily Chan, Rathi N Pillai, Filippo de Braud, Dung T Le, Chris Harbison, Chen-Sheng Lin, Marina Tschaika
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
See all 2 articles